Department of Internal Medicine, Medical University of Geraz
Graz, 8036, Austria
NCT Number: NCT01607528
Liver cirrhosis is the 10th most common cause of death in the western world. Infection is the most common precipitant of deterioration of liver function in cirrhosis. Endotoxin, derived from gram-negative organisms in the gut, can enter the circulation due to increased gut permeability and contributes to neutrophil dysfunction, infection risk and mortality in alcoholic cirrhotics. As probiotics decrease gram-negative organisms in the gut and/or decrease gut permeability, the investigators hypothesize that probiotic treatment would restore neutrophil function and prevent infection in alcoholic cirrhosis.
The investigators hypothesize that administration of a probiotic mixture in patients with liver cirrhosis will improve innate immune function through alteration of the gut bacterial flora and gut barrier integrity.
The aim of this randomised, double-blinded placebo-controlled study is to assess whether food supplementation with probiotic mixture improves neutrophil phagocytic capacity in patients with cirrhosis and decreases the incidence of significant infections.
92 patients with alcoholic cirrhosis will be included according to a sample size calculation from preliminary data. Patients will be randomized in two groups: Group 1 receives a probiotic mixture Group 2 receives a similar looking and tasting placebo without bacteria. The recruited patients will be treated for 6 months. Besides routine clinical and laboratory assessments, neutrophil function, toll-like receptor expression, endotoxin levels, bacterial DNA, cytokine levels, albumin oxidation, gut permeability and analysis of gut microflora will be performed. Furthermore nutritional status and quality of life will be assessed.
Primary endpoints will be neutrophil phagocytosis. Secondary endpoints will be significant infection, neutrophil oxidative burst, neutrophil toll-like receptor expression, endotoxin levels, bacterial DNA; cytokine levels, albumin oxidation, gut barrier function and bacterial flora, nutritional status and quality of life.
If our hypothesis holds true, probiotics will provide an easily applicable and cost effective method to improve immune function and to prevent infection in liver cirrhosis. It is possible that this can improve survival of patients with liver cirrhosis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Graz, 8036, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
• Patients aged between 18-80 years
Exclusion criteria
6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
A similar looking and tasting powder with no active substances
Time frame: Change from baseline to 6 months
Percentage of neutrophil granulocytes showing phagocytosis of FITC (fluorescein isothiocyanate) -labelled E.coli bacteria
Time frame: during 12 months
Occurence of infections that require specific treatment and/or hospitalisation during the study period of 12 months
Time frame: 0, 6, 12 months
Endotoxin in serum (EU/ml)
Time frame: 0, 6, 12 months
percentage of neutrophil granulocytes showing oxidative burst with and without stimulation and mean fluorescence activity
Time frame: 0, 6, 12 months
percentage of neutrophil granulocytes showing TLR (Toll-like receptor) 2, TLR4 or TLR9 expression and mean fluorescence activity
Time frame: 0, 6, 12 months
oxidative status of albumin in the plasma (percentage of (human mercaptalbumin) HMA, (human non-mercaptalbumin) HNA1 and HNA2)
Time frame: 0, 6, 12 months
elevation of one or more inflammatory markers: C reactive protein (mg/ml), lipopolysaccharide binding protein (ng/ml), soluble CD (cluster of differentiation) 14 (ng/ml)
Time frame: 0, 6, 12 months
isolation of bacterial DNA and sequencing the gut microbiome from stool and duodenal aspirate
Time frame: 0, 6, 12 months
(short form) SF-36 questionaire
Time frame: 0,6, 12 months
subjective global assessment
Time frame: 0, 6, 12 months
elevated lactulose mannitol ratio, elevated zonulin
Medical University of Graz
Other
Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections
Acronym: PIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07701031
Digestive System Diseases, Fibrosis
Münster, Germany
View Trial DetailsNCT06708832
Digestive System Diseases, Fibrosis
Graz, Austria
View Trial DetailsNCT07625085
Digestive System Diseases, Fibrosis
Rome, Lazio, Italy
View Trial DetailsNCT01082419
Adenocarcinoma, Biliary Cholestasis
Bordeaux, France
View Trial Details